[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335734-105":59,"doc-detail-335734-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","camrelizumab-combined-with-gemcitabine-and-apatinib-in-treating-advanced-pd-l1-positive-biliary-tract-cancers","Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers","","Combined chemotherapy and immunotherapy has shown benefit in biliary tract cancer, motivating evaluation of camrelizumab with gemcitabine and apatinib in advanced PD-L1-positive disease. This prospective, single-arm exploratory trial enrolled 20 PD-L1-positive patients (TPS ≥1% or CPS ≥1) for first- or second-line treatment. Camrelizumab 200 mg was given with gemcitabine 800 mg/m2 and apatinib 250 mg, with objective response rate as the primary endpoint and progression-free survival, overall survival, disease control rate, and safety as secondary endpoints. Fourteen patients were enrolled; the ORR was 42.9% and DCR 71.4%, with median PFS 5.4 months and median OS 13.5 months. Neutropenia was the most frequent grade 3–4 treatment-related adverse event, and the regimen showed promising efficacy with acceptable safety.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/camrelizumab-combined-with-gemcitabine-and-apatinib-in-treating-advanced-pd-l1-positive-biliary-tract-cancers/335734/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/camrelizumab-combined-with-gemcitabine-and-apatinib-in-treating-advanced-pd-l1-positive-biliary-tract-cancers/335734.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main goal?","Question",{"text":112,"@type":113},"To assess the efficacy and safety of camrelizumab combined with gemcitabine and apatinib as a first- or second-line treatment for advanced PD-L1-positive biliary tract cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were PD-L1-positive patients selected?",{"text":117,"@type":113},"Patients were required to be PD-L1-positive with tumor proportion score (TPS) ≥1% or combined positive score (CPS) ≥1, and meet the inclusion criteria.",{"name":119,"@type":110,"acceptedAnswer":120},"What endpoints and outcomes were reported?",{"text":121,"@type":113},"The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety, with ORR 42.9% and DCR 71.4% reported.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335734,1790115024,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","DOI: 10. 1111/cas.16376  \nOR I G I NAL ART I C L E  \nCamrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers  \nYitong Tian1,2  | Changxian Li3 | Ke Jin4 | Ling Ma1 | Jiaguang Zhang1 | Xinyi Zhang1 | Wei You3 | Haoyang Shen1 | Yuting Ding1 | Hao Qian1 | Xiangcheng Li3 | Xiaofeng Chen1,5,6,7   \n1Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China  \n2Department of Oncology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China 3 Hepatobiliary Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China  \n4Department of Medical Oncology, Liyang People's Hospital, Liyang, China  \n5Gusu School, Nanjing medical University, Suzhou, China  \n6Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China  \n7Department of Oncology, Nanjing Pukou People's Hospital, Nanjing, China  \nCorrespondence  \nXiaofeng Chen and Xiangcheng Li, Jiangsu Provincial People's Hospital, 300 Guangzhou Road, Nanjing 210029, Jiangsu, China.  \nEmail: [chenxiaofengnjmu@163.com](chenxiaofengnjmu@163.com) and [drxcli@njmu.edu.cn](drxcli@njmu.edu.cn)  \nFunding information  \nBeijing Xisike Clinical Oncology Research Foundation, Grant/Award Number: YHR2019-0367; Science and Technology Development Fund project of Pukou Branch of Jiangsu Provincial People's Hospital in 2021, Grant/Award Number:  \nKJ2021-1  \nAbstract  \nThe efficacy of combined chemotherapy and immunotherapy has previously been demonstrated in patients with biliary tract cancer. The aim of this study was to assess the efficacy and safety of camrelizumab in combination with gemcitabine and apatinibas a first-or second-line treatment for advanced programmed death-ligand 1 (PD-L1) -positive biliary tract cancer. This prospective, single-arm, and exploratory clinical trial aimed at recruiting 20 PD-L1-positive patients (tumor proportion score ≥1% or combined positive score ≥1) who met the inclusion criteria. Camrelizumab (200 mg) was administered in combination with gemcitabine (800 mg/m2) and apatinib (250 mg) . The primary endpoint was the objective response rate (ORR), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Fourteen patients were enrolled between September 2, 2020, and December 15, 2022. At the data cutoff on August 16, 2023, the median follow-up time was 11.4 months (interquartile range, 4.5–15.4), with one patient still undergoing treatment. Among the enrolled patients, six achieved a partial response, and four had stable disease. The ORR was 42 .9%(95% confidence interval [CI], 17.7–71. 1), and the DCR was 71.4%(95% CI, 41.9–91. 6) . The median PFS was 5.4 months (95% CI, 2. 8–not reached), and the median OS was 13.5 months (95% CI, 5 .7–not reached) . The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n = 4,  \n29%) . The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.  \nK E Y WO R D S  \nadvanced biliary tract cancer, apatinib, camrelizumab, gemcitabine, PD-L1 positive  \nYitong Tian, Changxian Li and Ke Jin contributed equally to this work.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2024 The Author(s) . Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.  \n1 | INTRODUCTION  \nBiliary tract cancer (BTC) is an invasive adenocarcinoma that includes cholangiocarcinoma (cancers originating in the intrahepatic, perihilar, or distal biliary tree) and gallb","cbCaiv4lmvUQNBf7","https://ap.wps.com/l/cbCaiv4lmvUQNBf7","pdf",748471,"English","# Abstract\n# Introduction\n## Background on biliary tract cancer\n## Prior chemotherapy regimens\n## Immunotherapy evidence and limitations\n## Prior combination studies and rationale","[{\"question\":\"What was the study’s main goal?\",\"answer\":\"To assess the efficacy and safety of camrelizumab combined with gemcitabine and apatinib as a first- or second-line treatment for advanced PD-L1-positive biliary tract cancer.\"},{\"question\":\"How were PD-L1-positive patients selected?\",\"answer\":\"Patients were required to be PD-L1-positive with tumor proportion score (TPS) ≥1% or combined positive score (CPS) ≥1, and meet the inclusion criteria.\"},{\"question\":\"What endpoints and outcomes were reported?\",\"answer\":\"The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety, with ORR 42.9% and DCR 71.4% reported.\"}]","Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers | PDF",1790012155,25]